A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of the long-term use of pregabalin at doses up
to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study
A0081208 (NCT00830167).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.